NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=143343&from=4 CLASS PERIOD: Mar ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) investors of a class action representing investors that bought securities between March 17, 2023 to November 4, 2024, inclusive (the "Class Period"). SANA investors have until May 20, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Po ...

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www ...

Core Viewpoint - The article discusses the investigation into Sana Biotechnology, Inc. for potential securities law violations, highlighting significant financial risks and operational changes that have impacted the company's stock performance. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, reminding investors of the May 20, 2025 deadline to seek lead plaintiff status in a federal securities class action [2] - The complaint alleges that Sana and its executives made false or misleading statements regarding the company's financial health and product development [4] Group 2: Financial Performance and Operational Changes - On October 10, 2023, Sana announced a reduction in near-term spending on its fusogen platform and a 29% headcount reduction, aiming to keep its 2024 operating cash burn below $200 million [5][6] - Following this announcement, Sana's stock price fell by $0.34 per share, or 8.95%, closing at $3.46 per share [6] - On November 4, 2024, Sana announced the suspension of development for SC291 and SC379, reallocating resources to its type 1 diabetes program, which extended its cash runway into 2026 [7] - This announcement led to a further decline in stock price by $0.37 per share, or 9.84%, closing at $3.39 per share [7]

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Faruqi & Far ...

NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com ...

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and product development capabilities [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain operations and advance its product candidates [2]. - Specific product candidates, including SC291 in oncology, SC379, and SG299, were reportedly less promising than what the company had communicated to investors [2]. - To conserve cash and focus on more promising candidates, Sana was likely to reduce funding for or discontinue certain projects and significantly cut its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to sustain operations and advance existing product candidates [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 20, 2025 [3]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3]. Group 3: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, Inc. due to allegations of misleading statements regarding the company's financial health and product development, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 20, 2025 [2][4]. Group 1: Allegations Against Sana - The complaint alleges that Sana and its executives violated federal securities laws by making false or misleading statements about the company's financial stability and product candidates [4]. - Specific claims include that Sana was at significant risk of insufficient funds to maintain operations and that certain product candidates were less promising than previously stated [4]. - The company is accused of overstating its financial capacity and failing to disclose plans to reduce funding for certain projects and decrease its workforce [4]. Group 2: Recent Developments - On October 10, 2023, Sana announced a reduction in spending on its fusogen platform and a 29% headcount reduction, aiming to keep its 2024 operating cash burn below $200 million [5][6]. - Following this announcement, Sana's stock price fell by $0.34 per share, or 8.95%, closing at $3.46 per share [6]. - On November 4, 2024, Sana suspended development of two product candidates and shifted focus to its type 1 diabetes program, which led to a further stock price decline of $0.37 per share, or 9.84%, closing at $3.39 per share [7].

NEW YORK, April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com ...